Standard Operating Procedure for Handling Serious Adverse Events (SAEs) in BA/BE Studies
Department | BA-BE Studies |
---|---|
SOP No. | SOP/BA-BE/068/2025 |
Supersedes | SOP/BA-BE/068/2022 |
Page No. | Page 1 of 11 |
Issue Date | 17/04/2025 |
Effective Date | 20/04/2025 |
Review Date | 17/04/2026 |
1. Purpose
To provide a clear, standardized procedure for the identification, assessment, documentation, management, and reporting of Serious Adverse Events (SAEs) in Bioavailability/Bioequivalence (BA/BE) studies.
2. Scope
This SOP applies to all clinical personnel and investigators involved in the monitoring, documentation, and reporting of SAEs that occur during BA/BE studies conducted at the clinical research unit.
3. Responsibilities
- Investigator: Evaluates and confirms SAE status, determines causality, and signs off SAE forms.
- Clinical Research Coordinator (CRC): Assists with documentation and ensures regulatory timelines are met.
- Nursing Staff: Provides initial emergency care and informs the medical team immediately.
- QA/Regulatory Affairs: Submits reports to ethics committees, sponsors, and regulatory bodies.
4. Accountability
The Principal Investigator is accountable for ensuring that all SAEs are identified promptly, managed appropriately, and reported within prescribed regulatory timelines.
5. Procedure
5.1 Definition of SAE
- Any untoward medical occurrence that:
- Results in death
- Is life-threatening
- Requires hospitalization or prolongation of hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
5.2 Identification and Initial Response
- Nursing staff shall notify the Investigator immediately upon observation or report of any SAE-like symptoms.
- Provide emergency medical care and stabilize the subject.
- Document time of event and action taken in Annexure-1: SAE Initial Management Log.
5.3 Medical Assessment
- The Investigator assesses:
- Severity and seriousness
- Causality (related/unrelated/possibly related)
- Outcome and need for hospitalization
- Details entered into Annexure-2: SAE Reporting Form.
5.4 Regulatory Reporting
- Report to the Sponsor, Ethics Committee, and Regulatory Authority (e.g., CDSCO) within 24 hours of awareness.
- Follow up with a detailed SAE report within 7 calendar days.
- Maintain submission proof in Annexure-3: Regulatory Communication Log.
5.5 Follow-Up and Final Assessment
- Conduct follow-up until resolution or stabilization of SAE.
- Update the SAE form and CRF with final outcome and Investigator signature.
- Attach supporting documents (discharge summary, lab results, etc.).
5.6 Review and Archival
- All SAE forms and documentation are reviewed by QA for completeness.
- Archived in Trial Master File (TMF) under safety documentation.
6. Abbreviations
- SAE: Serious Adverse Event
- AE: Adverse Event
- CRF: Case Report Form
- PI: Principal Investigator
- CDSCO: Central Drugs Standard Control Organization
7. Documents
- SAE Initial Management Log – Annexure-1
- SAE Reporting Form – Annexure-2
- Regulatory Communication Log – Annexure-3
8. References
- ICH E6(R2) – Good Clinical Practice
- ICH E2A – Clinical Safety Data Management
- CDSCO SAE Reporting Guidelines
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: SAE Initial Management Log
Subject ID | Date & Time | Event Description | Immediate Action Taken | By Whom |
---|---|---|---|---|
VOL-068 | 17/04/2025, 09:05 | Severe hypotension | Oxygen and IV fluids | Dr. Arvind Shah |
Annexure-2: SAE Reporting Form
Subject ID | Event | Start Date | Severity | Causality | Outcome |
---|---|---|---|---|---|
VOL-068 | Syncope | 17/04/2025 | Severe | Possibly Related | Recovered |
Annexure-3: Regulatory Communication Log
Report Type | Sent To | Date Sent | By Whom | Acknowledgment |
---|---|---|---|---|
Initial SAE Report | CDSCO | 17/04/2025 | Nisha Verma | Yes |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
10/01/2022 | 1.0 | Initial release | Study compliance | QA Head |
17/04/2025 | 2.0 | Added regulatory log, annexure details | Regulatory update | QA Head |